⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 4, 2024Open Access

Figure S7 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies

Christianne Groeneveldt Priscilla Kinderman Lisa Griffioen Olivia Rensing Camilla Labrie Diana J.M. van den Wollenberg Rob C. Hoeben Matt Coffey Houra Loghmani Els M.E. Verdegaal Marij J.P. Welters Sjoerd H. van der Burg Thorbald van Hall Nadine van Montfoort

View Full Paper

Ask AI

Bookmark

Share

Abstract

Figure S7. Reo-specific neutralizing antibodies are present 5 days after intratumoral Reo administration.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Groeneveldt et al. (2024) studied this question.

synapsesocial.com/papers/68e75dd0b6db6435876d4bf9 https://doi.org/10.1158/2326-6066.25338115.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S5 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies2024
2Figure S15 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies2024
3Figure S9 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies2024
4Figure S6 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies2024
5Figure S10 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies2024

More related papers

Figure S4 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies2024
Figure S3 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies2024
Figure S12 from Neutralizing Antibodies Impair the Oncolytic Efficacy of Reovirus but Permit Effective Combination with T cell–Based Immunotherapies2024